围。 | NVO 诺和诺德 | | | | --- | --- | --- | | 47 07 0 J -2.960 -5.92% | | 收盘价 07/31 15:59 美东 | | 48.100 t 1.030 +2.19% | | 盘前价 08/01 07:41 美东 | | 一 2 24 4 (3 ) 8 日 (0 自选 | | ● 快捷交易 | | 最高价 49.300 | 开盘价 48.960 | 成交量 5037.25万 | | 最低价 46.900 | 昨收价 50.030 | 成交额 24.32亿 | | 平均价 48.275 | 市盈率 TM 13.11 | 总市值 2090.22亿 …) | | 振 幅 4.80% | 市空率(静) 13.60 | 总股本 44.41亿 | | 换手率 1.58% 市净率 9.863 | | 流通值 1501.48亿 | | 52周最高 137.431 委 比 -60.00% | | 流通股 31.9亿 | | 52周最低 46.900 量 比 1.24 | | 笹 手 1股 | | 历史最高 145.160 股息TTM 1.603 | | | | 历史 ...

Danish drugmaker Novo Nordisk was at the forefront of the weight-loss injection boom but failed to keep up with runaway demand and misjudged the speed and scale of competition. Here’s what to know. https://t.co/ClOj5ourqi ...

8月1日，欧洲主要股指开盘集体下跌。药企巨头美股盘前全线下挫。 德国DAX30指数跌逾1%，英国富时100指数小幅下跌，法国CAC40指数跌超0.8%。欧洲斯托克50指数盘中跌幅扩大至逾1%。 美国股指期货触及盘中低点，纳斯达克100指数期货下跌0.9%。 消息面上，在美国设定的"对等关税"谈判期限即将到期之际，美国政府于当地时间7月31日出台"新政"，确定了对多个国家和地区征收"对等关税"的新税 率，具体税率从10%至41%不等。新关税政策将于7天内生效。 相关专家表示，此次新关税政策的税率逐渐清晰、目标更为明确，这可能会加剧全球供应链的分割，但关税新政能否在中长期持续，还要取决于美国经济 的承受能力、国际反制力度以及政治博弈的结果。但全球贸易体系或将加快向区域化演进。 药企巨头美股盘前集体下跌，诺和诺德跌逾2%，阿斯利康跌超1.7%，礼来小幅下跌。 美国总统特朗普周四表示，他已要求全球主要制药公司在未来60天内采取措施降低美国药品价格。 部分内容综合自环球时报 责编：梁秋燕 ...

Novo Nordisk loses its spot among Europe's 10 most valuable firms https://t.co/vYnsLsmFQ6 ...

格隆汇8月1日｜美国总统特朗普周四致函欧洲制药公司，要求其将美国消费者的药品价格降至其他发达 国家的最低水平，导致欧洲制药公司股价早盘下跌。葛兰素史克、阿斯利康、诺和诺德和赛诺菲的股价 分别下跌1.7%、2.8%、4.2%和1.2%，诺和诺德股价跌至四年低点。斯托克欧洲600医疗保健指数下跌 1.8%。 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com (责任编辑：宋政 HN002) ...

Core Viewpoint - Eli Lilly's GLP-1 weight loss drug, Tirzepatide, shows cardiovascular benefits in a large-scale clinical study, intensifying competition with Novo Nordisk [3][4]. Group 1: Clinical Study Results - The SURPASS-CVOT Phase 3 study included data from China and compared Tirzepatide with Dulaglutide, an older diabetes drug from Eli Lilly, focusing on cardiovascular outcomes [3]. - Tirzepatide demonstrated non-inferior cardiovascular health benefits compared to Dulaglutide, positioning it as a preferred prescription for type 2 diabetes patients [3][4]. - Eli Lilly plans to submit data to global regulatory agencies by the end of this year, with expectations for cardiovascular indications approval in 2026 [3]. Group 2: Market Context and Competition - In China, Tirzepatide has received approvals for diabetes management, weight loss, and obstructive sleep apnea, but not yet for cardiovascular indications [3]. - Novo Nordisk's Semaglutide already includes cardiovascular outcome benefits in its labeling, highlighting the competitive landscape [3][4]. - Novo Nordisk recently lowered its sales growth forecast for Semaglutide in the U.S. market from 13%-21% to 8%-14% for 2025, indicating potential market challenges [4].

来源：格隆汇APP 格隆汇8月1日｜美国总统特朗普周四致函欧洲制药公司，要求其将美国消费者的药品价格降至其他发达 国家的最低水平，导致欧洲制药公司股价早盘下跌。葛兰素史克、阿斯利康、诺和诺德和赛诺菲的股价 分别下跌1.7%、2.8%、4.2%和1.2%，诺和诺德股价跌至四年低点。斯托克欧洲600医疗保健指数下跌 1.8%。 ...

特朗普要求降低药品价格后，欧洲制药股下跌 金十数据8月1日讯，美国总统特朗普周四致函欧洲制药公司，要求其将美国消费者的药品价格降至其他 发达国家的最低水平，导致欧洲制药公司股价早盘下跌。葛兰素史克、阿斯利康、诺和诺德和赛诺菲的 股价分别下跌1.7%、2.8%、4.2%和1.2%，诺和诺德股价跌至四年低点。斯托克欧洲600医疗保健指数下 跌1.8%。 ...

诺和诺德欧股股价跌至2022年1月低点，连续第三天下跌。 ...

Core Insights - The core finding of the articles is that the GLP-1 weight loss drug, Tirzepatide, shows comparable cardiovascular benefits to Dulaglutide, positioning it as a potential preferred prescription for type 2 diabetes patients [1][2] Group 1: Clinical Study Results - Eli Lilly announced the results of a large-scale clinical study, SURPASS-CVOT, indicating that Tirzepatide demonstrates cardiovascular benefits similar to Dulaglutide [1] - The study included data from China and compared the cardiovascular outcomes of Tirzepatide and Dulaglutide, which is set to lose its patent in 2027 [1] - Eli Lilly plans to submit data to global regulatory agencies by the end of this year, with expectations for cardiovascular indications to be approved by 2026 [1] Group 2: Market Competition - The competition between Eli Lilly and Novo Nordisk is intensifying, particularly in the U.S. market [2] - Novo Nordisk recently revised its sales growth forecast for Semaglutide in the U.S. market from 13%-21% to 8%-14% due to declining growth expectations [2] - Eli Lilly is set to release its latest quarterly financial report on August 7 [2] Group 3: Health Implications - Cardiovascular disease remains a leading cause of death among type 2 diabetes patients, highlighting the importance of effective treatment options [2] - The SURPASS-CVOT results suggest that Tirzepatide not only retains the cardiovascular protective effects of Dulaglutide but also offers additional health improvements, including enhanced kidney protection and reduced overall mortality risk [2] - In China, nearly 70% of type 2 diabetes patients are at high risk for cardiovascular disease and kidney disease, emphasizing the need for improved management strategies [2]